He is a member of the IOM and has served on 5 previous Academy committees, including the Committee on Organ Procurement and Transplantation Policy, which he chaired. He served on the Commission of Life Sciences Board from 1995-1998 and currently serves on the STEP board.

Technology Assessment; Epidemiology

Diana B. Petitti, M.D., M.P.H. is Director of Research and Evaluation, Southern California Permanente Medical Group. Dr. Petitti received her M.D. degree from Harvard Medical School in 1975. After an internship in Medicine at the University of Colorado Affiliated Hospitals, she spent two years as an Epidemic Intelligence Service Officer with the Centers for Disease Control. She first joined Kaiser Permanente in 1978 as an Epidemiologist in the Division of Research in Northern California. In 1981, she received her M.P.H. in epidemiology from the Berkeley School of Public Health. In 1984, she left Kaiser Permanente to join the full-time faculty at the University of California, San Francisco School of Medicine, where she stayed until rejoining Kaiser Permanente Southern California in 1993 as the Director of Research and Evaluation.

Dr Petitti’s expertise includes epidemiology, health coverage and reimbursement policy, cost-effectiveness analysis, and health services research. She has also written on women’s health issues. Dr. Petitti is vice-chair of the National Cancer Policy Board and has been a member since 1997. She served on the Board on Health Promotion and Disease Prevention from 1995-1997.

Diagnostic Radiology

Etta Pisano, M.D. is the Director of Breast Imaging at University of North Carolina Hospitals and is a practicing Radiologist. She is also a Professor in Radiology and Adjunct Professor in Biomedical Engineering at University of North Carolina School of Medicine. Dr. Pisano received her M.D. from Duke University and completed her Clinical Fellowship in Radiology at Harvard Medical School. She is a member of the Radiological Society of North America; has been Chair of the American College of Radiology Imaging Network since 1999 and Vice President of the Association of University Radiologists since 2001. She is Chair of the International Digital Mammography Development Group and a fellow of the Society of Breast Imaging. She serves on the National Institutes of Health’s study section on Applied Science and Technology and on the U.S. Food and Drug administration’s National Quality Assurance Advisory Committee. Dr. Pisano was acknowledged as one of the 20 most influential radiologists in 2002, by the American College of Radiology.

Biostatistics; Clinical Trial Design

Colin Begg, Ph.D. is Chairman of the Department of Epidemiology and Biostatistics and Chairman of the Prevention Control and Population Research Program at Memorial Sloan-Kettering Cancer Center. Dr. Begg received his Ph.D. in Statistics from the University of Glasgow. His research expertise is in statistical methodology, and he has significant interests in cancer epidemiology and health services research. Dr. Begg is an expert on biostatistical techniques used in clinical trials, studies to evaluate diagnostic tests, and epidemiologic studies of factors that influence cancer incidence. He has been particularly interested in statistical biases that affect results from these kinds of studies and has been working to increase awareness of these biases and to improve the quality of reports of studies published in medical journals. He has held academic positions at the State University of New York at Buffalo, Harvard School of Public Health, and currently holds a position at Cornell Medical School. He is an elected fellow of the American Statistical Association, and the International Statistical Institute.

Health Care Delivery; Technology Adoption

Glenn D. Steele, M.D., Ph.D. is President and CEO of the Geisinger Health System in Danville, Pennsylvania. Before that, Dr. Steele spent six years at the University of Chicago where he served as the Richard T. Crane Professor in the Department of Surgery, Vice President for Medical Affairs and Dean of the Biological Sciences and the Pritzker School of Medicine. Prior to that, he was the William V. McDermott Professor of Surgery at Harvard University Medical School and Chairman of the Department of Surgery of New England Deaconess Hospital. In July 2002 he was one of five rural health experts appointed to serve on the 16-member National Advisory Committee on Rural Health.

Dr. Steele is widely recognized for his investigations into the treatment of primary and metastatic liver cancer and colorectal cancer surgery. He is the immediate past Chairman of the American Board of Surgery. His laboratory investigations have focused on the cell biology of gastrointestinal cancer and pre-cancer. He is an IOM member and his expertise and competency includes federal agency administration, hospital/medical center administration, biology, immunology, molecular biology, oncology, history, colon & rectal surgery, medical oncology, surgery.


Health Care Policy; Radiology

Barbara McNeil, M.D., Ph.D. is the Ridley Watts Professor and founding Head of the Department of Health Care Policy at Harvard Medical School. She is also a Professor of Radiology at Harvard Medical School and at Brigham and Women's Hospital.

Dr. McNeil's research activities focus on quality of care from a variety of perspectives. These include three primary areas: 1) the development and implementation of quality measures for chronic cardiac diseases, 2) the role of financial incentives and managerial practices in assuring quality, and 3) the assessment of the extent to which adherence to guidelines for care actually improves outcomes of care. She also recently completed a ten-year multi-institutional study on the relative benefits of a variety of radiology approaches to the initial and subsequent management of patients with cancer.

Dr. McNeil is a member of the IOM, and member of the national Blue Cross Technology Assessment Commission, the Council for Performance Measurement for the JCAHO, and previously served as a member of the Prospective Payment Assessment Commission and as chair of its subcommittee on diagnostic and therapeutic practices. She has served on the IOM Board on Health Care Services since 1996 and is the current chair From 1991-1996, she served on the IOM Council and has served on more than half a dozen Academy committees.

Oncology; Therapeutics

Martin D. Abeloff, M.D. is Director of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Eli Kennerly Marshall, Jr. Professor of Oncology, and Oncologist-in-Chief of the Johns Hopkins Hospital and Health Systems in Baltimore Maryland. He is a medical oncologist whose major research focus has been the management of solid tumors, particularly those located in the breast or lung.

He has been deeply committed to translational research, specifically in the treatment for breast cancer and lung cancer. He was responsible for the development of the solid tumor clinical research programs in the Oncology Center in the early 1970s and has played a leadership role in the development of broad-based research programs in solid tumors, hematologic malignancies and in cancer prevention and control.

At the national level, he served as President of the American Society of Clinical Oncology in 1991-92 and as Chairman of the Oncology Drug Advisory Committee of the FDA. He was the Chairman of the Board of Scientific Counselors to the NCI's Intramural Division of Clinical Sciences at the National Cancer Institute from 1995 to 2001. In 1989, he served on the IOM Committee to Conduct a Workshop on the Development of a Research Agenda Concerning Medical Diagnosis and Treatment of Breast Cancer.

Surgical Oncology; Clinical Trials

William C. Wood, M.D. is Chief of Surgery at Emory University Hospital and Chair of Ethics Committee, Emory University Hospital. Dr. Wood is on the Board of Governors of the American College of Surgeons; co-chair of the Early Breast Cancer Trialists' Collaborative Group, Chairman, NIH Consensus Group on the Management of Early Breast Cancer; NIH, serves on the NCI Board of Scientific Advisors; NCI Intergroup Committee of Cooperative Group Breast Committee Chairs: is Chair of the Eastern Cooperative Oncology Group: Vice-Chair of the Breast Committee for the Medical Advisory Board of the National Alliance of Breast Cancer Organizations, and an honorary fellow of the Royal College of Surgeons of England, past-president of the Society of Surgical Oncology., and Editor-in-Chief of Oncology.

Dr. Wood has received over a dozen national awards for being one of the nation’s "top doctors." Five of these awards are: "America's Top Doctors for Women," from Ladies Home Journal in 2002; "America's Top Breast Cancer Doctors," from Redbook in 2001; "America's Top Rated Physicians," Guide to Top Doctors, 1999; "The Best Doctors in America," American Health, 1996; "Outstanding Medical Specialists in the US," Town and Country, 1989.

In June 2002, Dr. Wood co-chaired the Global Summit on Mammography. His research interests include predicting breast cancer outcomes and ethical applications in medicine and surgery, as well as cancer treatment and research, design of conceptually driven national clinical trials, and meta-analysis of clinical trials.

Health Care Consumer

Christine Brunswick is Vice-President of the National Breast Cancer Coalition Board of Directors and has been a member of the board since 1992. National Breast Cancer Coalition is a grassroots advocacy organization that works to increase funding for breast cancer research and to collaborate with the scientific community to implement new models of research and improve access to high quality health care and breast cancer clinical trials for all women. Ms. Brunswick has an accomplished history of promoting and advocating on behalf of many women's health issues. She participated in the programmatic review for the Department of Army Breast Cancer Research Program; the Food & Drug Administration working group on Drug Approval Process and Patient Involvement; and, was a participant and drafter of the United Nation's 4th World Conference on Women. She has spoken extensively at international health conferences and represented the NBCC at the United Nation's Conference on the Status of Women in the World. She is a member of the steering committee for Health Insight: Taking Charge of Health Information, a project that aims to help consumer evaluate health and scientific information and consider how the information can be used to improve their lives.

Ms. Brunswick is the director of the Section on Taxation for the American Bar Association, were she has worked since 1974. She is also a breast cancer survivor.

Molecular Biology; Cancer Biomarkers

Jeffrey Marks, Ph.D. is Head of the NCI-sponsored Early Detection Research Network Center and Associate Professor in Surgery at the Duke University Medical Center. Dr. Marks is a member of the NCI Steering Committee of the Cancer Biomarkers Research Group.

His research focuses on the molecular biology and genetics of breast cancer with an emphasis on understanding the genetic abnormalities that lead to the disease.

Molecular Imaging

Sanjiv Sam Gambhir, M.D., Ph.D. is director of the Crump Institute for Molecular Imaging UCLA School of Medicine and a member of the California Nanosystems Institute. He graduated from Arizona State University with a B.S. in Physics and then continued his education at UCLA, with first a Ph.D. in Biomathematics and then completing his M.D. shortly thereafter. Dr. Gambhir has remained at UCLA following his education first as an Assistant Professor in the Department of Molecular & Medical Pharmacology. He also held the position, Director of the Computational & Communication Sciences Division and was the Principle Investigator for the DOE Laboratory of Structural Biology and Molecular Medicine.

His research interests include developing imaging assays to monitor fundamental cellular events in living subjects, with the goal of integrating fundamental advances in molecular/cell biology with those in biomedical imaging to advance the field of molecular imaging. His particular focus is on cancer biology and gene therapy.

Dr. Gambhir has been lauded with awards both nationally and internationally. Within the past few years he has been given first prize by the Society of Nuclear Medicine for his exhibit on an internet-based clinical trials engine for information support of distributed clinical trials, presented an NAS Frontiers of Science Lecture on Molecular Imaging, and received the 2002 Talpin Award from the Society of Nuclear Medicine for his work on molecular imaging and reporter genes.

Bioinformatics; Radiology

Robert A. Greenes, M.D., Ph.D. is Professor of Health Policy and Management at the Harvard School of Public Health and Professor of Radiology, Harvard Medical School, as well as Professor in the Harvard-MIT Division of Health Sciences and Technology. He is a radiologist at Brigham and Women’s Hospital in Boston, MA. Dr. Greenes also serves as Program Director of the Harvard-MIT Research Training Program in Biomedical Informatics. Dr. Greenes established the Decision Systems Group (DSG), a Harvard-based biomedical informatics research and development laboratory at Brigham and Women’s Hospital, and is its Director. He serves on the board of directors for the not-for-profit Institute for Medical Knowledge Implementation (IMKI) and works with a wide variety of constituencies to further its mission of developing and maintaining a library of medical knowledge applications for use in clinical information systems.

He is also a co-principal investigator in the Columbia University-based InterMed Collaboratory, a collaboration of research labs that also include Stanford Medical Informatics (SMI) at Stanford University, and the DSG.

Dr. Greenes is a practicing radiologist and a leading informatics expert. His primary research focus is information architecture to support clinician access to the diverse information resources needed for patient care. The goal is to provide "seamless" integration of clinical data, images, decision support, and educational materials, on a problem-specific basis.

He is a fellow of the American College of Medical Informatics, the American College of Radiology, the Society for Computer Applications in Radiology, as well as an IOM member.

Technology Development; Imaging

Kirby G. Vosburgh, Ph.D. is Associate Director of the Center for Integration of Medicine and Innovative Technologies (CIMIT). At CIMIT, he also heads DOD collaborations and chairs Program Development. (CIMIT is a consortium of healthcare and research institutions founded by Partners Healthcare System, MIT, and Brigham and Women’s Hospital. Their mission is "to improve patient care by bringing together scientists, engineers, and clinicians to catalyze development of innovative technology, emphasizing minimally invasive diagnosis and therapy.) Dr. Vosburgh holds degrees in engineering and physics from Cornell and Rutgers, and conducted postdoctoral studies at Princeton. Before joining CIMIT, he managed R&D Laboratories for General Electric, where he lead teams which developed several GE products, including advanced MRI and ultrasound imagers, integrated circuits, software for NBC programming.

Dr. Vosburgh’s areas of interest include advanced medical technology for clinical care, including diagnosis, management of stroke, simulation, and trauma. He has been active for fifteen years in applying virtual reality techniques to medicine.

Biotechnology; Technology Investment

M. Kathleen Behrens, Ph.D. is Managing Director of RS Investments, an investment management firm based in San Francisco. She is responsible for investing venture capital in young biotechnology and healthcare companies. Previously, she worked at the firm of Robertson Stephens & Co. for 17 years where she served in a variety of positions in the medical, health care, and biotechnology groups as both a public market analyst and a venture capitalist. Dr. Behrens founded 3 biotech companies. She is a director of Abgenix, Inc. and HealthTrio and has been a board member of Protein Design Labs, Inc., Cell Genesys, InSite Vision, Inc. and COR Therapeutics. She holds a Ph.D. in microbiology from the University of California, Davis.

Dr. Behrens is a member of the President's Council of Advisors on Science and Technology and has been a member of the STEP board since 1997.

Economics & Technology Policy

David C. Mowery, Ph.D. is Milton W. Terrill Professor of Business and Director, Haas School Ph.D. Program at the University of California at Berkeley. Dr. Mowery has been at the Haas School of Business since 1988. Prior to that, he was at Carnegie Mellon, the National Research Council, and the Office of the U.S. Trade Representative.

His research interests include technological change, international trade, US technology policy, intellectual property, and the relationship between public policies and the private sector. He co-authored the book, Paths of Innovation: Technological Change in 20th-Century America, with Nathan Rosenberg. Dr. Mowery has served on a dozen Academy committees and panels.

Business & Technology Development

Richard Bohmer, M.D. M.P.H. is assistant professor at the Harvard Business School in the unit of Technology and Operations Management. Before joining the HBS faculty, Dr. Bohmer was a Senior Clinical Associate at Massachusetts General Hospital and the Clinical Director of Quality Improvement for four years. He was responsible for planning and implementing the clinical quality improvement program at the hospital. Dr. Bohmer also was a co-chair of the Project Support and Implementation Group of "Operations Improvement," a major process redesign effort at the MGH. Dr. Bohmer trained at the Auckland University School of Medicine and is a Family Practitioner. He attended the Harvard School of Public Health on a Fulbright Scholarship from where he graduated in 1993 with a Masters of Public Health in Health Care Management.

Dr. Bohmer’s research interests include technology adoption in health care, clinical process management and clinical quality improvement. He is collaborating on a large multi-site project to evaluate the determinants of learning during the introduction of new surgical technology into cardiac surgical departments, and is currently applying insights from this work to a study of process innovation in health care. He has taught and consulted on health management issues in numerous locations both in the US and internationally, and is the co-author of a number of papers on learning and technology adoption in the health care sector.

Breast Cancer Therapy Consultant

Larry Norton, M.D. is Attending Physician and Member, Memorial Hospital, and Head of the Solid Tumor Division, Memorial Sloan-Kettering Cancer Center. He is also the Medical Director of MSK-64th Street, which includes the Evelyn H. Lauder Breast Center and the Iris Cantor Diagnostic Center. He is Co-Director of MSKCC's Breast Cancer Disease Management Team, Chair of the Breast Committee of the NCI's Cancer and Leukemia Group B, and a Presidential Appointee to the National Cancer Advisory of the NCI. Dr. Larry Norton served as President of the American Society of Clinical Oncology for the 2001 term. Since its formation in 1993, Dr. Norton has served as head of the Medical Advisory Board of The Breast Cancer Research Foundation.

Dr. Norton has served on or chaired numerous committees of governmental and professional organizations, including the NCI's Cancer Clinical Investigations Review Committee, its Cooperative Breast Cancer Tissue Resource (Registry), and the Consensus Development Conference on Treatment of Early Stage Breast Cancer (1990). He has also served on several committees of the Institute of Medicine of the National Academy of Sciences. He is currently President of the Board of Directors, National Alliance of Breast Cancer Organizations (NABCO).

Dr. Norton is a leader in the development of drug treatments for breast cancer. His work has established the value of using sequential combinations of drugs -- a strategy designed to overcome different drug sensitivities among the cells in a tumor. His mathematical models have been used to design new anticancer therapies and to formulate new approaches to chemotherapy and hormonal therapy. His research includes the use of monoclonal antibodies to target growth factor receptors as a way of slowing or shrinking tumors; the study and identification of breast cancer genes; and the development of Taxol as a treatment for breast cancer.